In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD

Journal of the American Society of Nephrology

Volumn 16, Issue 4, 2005, Pages 1099-1107

  Memoli, Bruno ^a   Grandaliano, Giuseppe ^b   Soccio, Michela ^b   Postiglione, Loredana ^a   Guida, Brunella ^a   Bisesti, Vincenzo ^a   Esposito, Pasquale ^a   Procino, Alfredo ^a   Marrone, Daniela ^b   Michael, Ashour ^a   Andreucci, Michele ^a   Schena, Francesco Paolo ^b   Pertosa, Giovanni ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; CELLULOSE; CYTOKINE; IL6ST PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ADULT; ARTICLE; BLOOD CULTURE; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; HEMODIALYSIS; HUMAN; IN VIVO STUDY; KIDNEY FAILURE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; RNA SPLICING; ALTERNATIVE RNA SPLICING; ARTIFICIAL MEMBRANE; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; CELL MEMBRANE; CHEMISTRY; CHRONIC KIDNEY FAILURE; GENETICS; INSTRUMENTATION; METABOLISM; MIDDLE AGED; MONOCYTE; RENAL REPLACEMENT THERAPY; SOLUBILITY;

ADULT; ALTERNATIVE SPLICING; ANTIGENS, CD; CASE-CONTROL STUDIES; CELL MEMBRANE; CELLULOSE; CYTOKINE RECEPTOR GP130; CYTOKINES; FEMALE; GENE EXPRESSION; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANES, ARTIFICIAL; MIDDLE AGED; MONOCYTES; RECEPTORS, INTERLEUKIN-6; RENAL DIALYSIS; SOLUBILITY;

EID: 24344444890     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004080628     Document Type: Article

References (38)

1. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP: The pathophysiologic roles of interleukin 6 in human disease. Ann Intern Med 128: 127-137, 1998
2. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM: The soluble interleukin 6 receptor: Mechanisms of production and implications in disease. FASEB J 15: 43-58, 2001
3. Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol 54: 1-78, 1993
4. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454, 1999
5. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P: Interleukin 6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 17: 1684-1688, 2002
6. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P: Update on interleukin 6 and its role in chronic renal failure. Nephrol Dial Transplant 18: 1042-1045, 2003
7. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL: Interleukin 6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32: 107-114, 1998
8. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658, 1999
9. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35: 469-476, 2000
10. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin 6? Kidney Int 61[Suppl 80]: S103-S108, 2002
11. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T: Interleukin 6 triggers the association of its receptor with a possible signal transducer, gp 130. Cell 58: 573-581, 1989
12. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L: Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334: 297-314, 1998
13. 727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/ MKK-4 as signal transduction components. Biochem J 347: 89-96, 2000
14. Rose-John S, Ehlers M, Grotzinger J, Mullberg J: The soluble interleukin 6 receptor. Ann N Y Acad Sci 762: 207-220, 1995
15. Heinrich PC, Graeve L, Rose-John S, Schneider-Mergener J, Dittrich E, Erren A, Gerhartz C, Hemmann U, Lutticken C, Wegenka U, Weiergraber O, Horn F: Membrane-bound and soluble interleukin 6 receptor: Studies on structure, regulation of expression and signal transduction. Ann N Y Acad Sci 762: 222-236, 1995
16. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, Yancopoulos GD, Taga T, Kishimoto T: Soluble forms of the interleukin 6 signal-transducing receptor component gp 130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82: 1120-1126, 1993
17. Frieling JTM, van Hamersvelt HW, Wijdenes J, Hendriks T, Sauerwein RW, van der Linden CJ: Circulating concentrations of soluble interleukin 6 receptors gp80 and gp130 in chronic renal failure and effects of renal replacement therapy. Am J Nephrol 19: 571-575, 1999
18. + mobilization, while basal release is predominantly the product of differential mRNA splicing in THP-1 cells. Eur J Immunol 28: 3514-3522, 1998
19. Vermes C, Jacobs JJ, Zhang J, Firneisz G, Roebuck KA, Giant TT: Shedding of the interleukin 6 receptor (gp80) determines the ability of IL-6 to induce gp130 phosphorylation in human osteoblasts. J Biol Chem 277: 16879-16887, 2002
20. Mullberg J, Althoff K, Jostock T, Rose-John S: The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw 11: 27-38, 2000
21. Diamant M, Rieneck K, Mechti N, Zhang XG, Svenson M, Bendtzen K, Klein B: Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin 6 signal transducer gp130. FEBS Lett 412: 379-384, 1997
22. Memoli B, Libetta C, Rampino T, Dal Canton A, Conte G, Scala G, Ruocco MR, Andreucci VE: Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells. Kidney Int 42: 320-326, 1992
23. Libetta C, De Nicola L, Rampino T, De Simone W, Memoli B: Inflammatory effects of peritoneal dialysis: Evidence of systemic monocyte activation. Kidney Int 49: 506-511, 1996
24. Memoli B, Minutolo R, Bisesti V, Postiglione L, Conti A, Marzano L, Capuano A, Andreucci M, Balletta MM, Guida B, Tetta C: Changes of serum albumin and C-reactive protein are related to changes of interleukin 6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis 39: 266-273, 2002
25. Memoli B, Postiglione L, Cianciaruso B, Bisesti V, Cimmaruta C, Marzano L, Minutolo R, Cuomo V, Guida B, Andreucci M, Rossi G: Role of different dialysis membranes in the release of interleukin 6 soluble receptor in uremic patients. Kidney Int 58: 417-424, 2000
26. Pertosa G, Gesualdo L, Tarantino EA, Ranieri E, Bottalico D, Schena FP: Influence of hemodialysis on interleukin 6 production and gene expression by peripheral blood mononuclear cells. Kidney Int 43[Suppl 39]: S149-S153, 1993
27. Pertosa G, Grandaliano G, Gesualdo L, Ranieri E, Monno R, Schena FP: Interleukin 6, interleukin 8 and monocyte chemotactic peptide-1 gene expression and protein synthesis are independently modulated by hemodialysis membranes. Kidney Int 54: 570-579, 1998
28. Zaoui P, Hakim RM: The effect of the dialysis membrane on cytokine release. J Am Soc Nephrol 4: 1711-1718, 1994
29. Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA: Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 45: 890-896, 1994
30. Dinarello CA: The role of the interleukin 1-receptor antagonist in blocking inflammation mediated by interleukin 1. N Engl J Med 343: 732-734, 2000
31. Nold M, Goede A, Eberhardt W, Pfeilschifter J, Muhl H: IL-18 initiates release of matrix metalloproteinase-9 from peripheral blood mononuclear cells without affecting tissue inhibitor of matrix metalloproteinase-1: Suppression by TNFα blockage and modulation by IL-10. Naunyn-Schmiedebergs Arch Pharmacol 367: 68-75, 2003
32. Gaillard JP, Mani JC, Liautard J, Klein B, Brochier J: Interleukin 6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin 6. Eur Cytokine Netw 10: 43-48, 1999
33. Gaillard JP, Pugniere M, Tresca JP, Mani JC, Klein B, Brochier J: Interleukin 6 receptor signaling. II. Bio-availability of interleukin 6 in serum. Eur Cytokine Netw 10: 337-344, 1999
34. Muller-Newen G, Kuster A, Hemmann U, Keul R, Horsten U, Martens A, Graeve L, Wijdenes J, Heinrich PC: Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 161: 6347-6355, 1998
35. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S: Soluble gp130 is the natural inhibitor of soluble interleukin 6 receptor transsignaling responses. Eur J Biochem 268: 160-167, 2001
36. Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H: Interleukin 6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 31: 93-100, 1998
37. Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J: Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 15: 953-960, 2000
38. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9[Suppl]: S16-S23, 1998